Cancer drugs fund threatens NHS England's bottom line

Paul Baumann

The NHS commissioning system is forecast to miss its target surplus by £184m in 2014-15, with much of the overspend attributed to the cancer drugs fund

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here